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Jemal et al use SEER data from 2010 to 2013 and fail to find an increase in the incidence of metastatic disease in this same age group. Hu et al claim that this discrepancy is due to differences in the choice of staging system used in the analysis, and they argue that if Jemal et al had used yearly incidence ratio analyses, they would have found an increasing rate of metastatic disease.
Frankly I tend to agree with Thomas and Shyr, whose thoughtful editorial comment accompanying the article by Hu et al attributes the contradictory results to "statistical random variation of incidence that can change over time depending upon the frequency of measurement."
1 They conclude that clinicians need to be cautious in interpreting the results of these studies, and I completely agree. Urologists are right to be concerned about the potentially deleterious effects of the 2008 and 2012 USPSTF recommendations against prostate cancer screening. That said, we also have to provide solid scientific evidence to back up our arguments, and frankly it is probably still too early to see the impact of the recommendations, given prior studies that imply the lead time associated with prostate specific antigen testing may be a decade or more.
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